Sequential Launch Planned in Local Markets

Daewoong Pharmaceutical announced on May 27 that it has obtained marketing approval in Mexico for Envlo (ingredient name: inavogliflozin), its type 2 diabetes treatment. With this, the company has expanded its presence in Latin America to a total of seven countries, accelerating its global expansion strategy.


Product image of Enblo, a type 2 diabetes treatment in the SGLT-2 inhibitor class developed by Daewoong Pharmaceutical. Daewoong Pharmaceutical

Product image of Enblo, a type 2 diabetes treatment in the SGLT-2 inhibitor class developed by Daewoong Pharmaceutical. Daewoong Pharmaceutical

View original image

This approval is part of Daewoong Pharmaceutical’s strategy to secure regulatory approvals for Envlo in 12 Latin American countries. The company has already signed supply agreements with its local partner Arcera (formerly Moksha8) for key markets, including Brazil and Mexico.


Daewoong Pharmaceutical explained that, since the majority of Latin America's total economic output is concentrated in these 12 countries, it expects a significant first-mover advantage in the region’s major markets. Starting this year, the company plans to sequentially launch its product throughout Latin America, leveraging local distribution networks.


Envlo is a domestically developed new drug in the SGLT-2 inhibitor class, created by Daewoong Pharmaceutical. Its mechanism involves lowering blood sugar by inhibiting the reabsorption of glucose in the kidneys. The company noted that Envlo demonstrated a similar glucose-lowering effect at a low dose of 0.3 mg, compared to existing SGLT-2 inhibitors.


Daewoong Pharmaceutical also reported that Envlo showed the potential to improve several indicators in patients with diabetes and impaired renal function, including the urinary glucose-to-creatinine ratio (UGCR), insulin resistance index (HOMA-IR), albuminuria, and NT-proBNP.



Sungsoo Park, CEO of Daewoong Pharmaceutical, stated, "This approval in Mexico is the first result of our strategy to expand into the Latin American market. We plan to accelerate local commercialization and broaden supply across the entire region."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing